Clinical trial
Study of Aranesp to Treat Anemia in Prostate Cancer Patients.
NCT00245895 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00245895 |
|---|---|
| Title | Study of Aranesp to Treat Anemia in Prostate Cancer Patients. |
| Official title | Phase II Study of Aranesp (Darbepoetin Alfa) to Treat Anemia in Prostate Cancer Patients. |
| Lead sponsor | University of Washington, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Anemia |
| Intervention type | Drug |
| Interventions | Aranesp |
| Enrollment | 20 |
| Start date | Apr 1, 2003 |
| Completion | Feb 1, 2005 |
| First posted | Oct 28, 2005 |
| Last update posted | Nov 29, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: